Singapore markets closed

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
3.2500+0.1200 (+3.83%)
At close: 04:00PM EDT
3.2500 0.00 (0.00%)
After hours: 07:41PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.1300
Open3.6400
Bid2.5600 x 200
Ask3.2900 x 100
Day's range3.2000 - 3.6400
52-week range2.9200 - 44.0000
Volume147,435
Avg. volume32,291
Market cap8.169M
Beta (5Y monthly)0.31
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Longeveron Announces 1-for-10 Reverse Stock Split

    MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that the Company’s Board of Directors has approved a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (the “common stock”) (the “Reverse Split”). The Reverse Split was previously approved by

  • GlobeNewswire

    Longeveron Reports Year-End 2023 Results and Provides Corporate Update

    Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Long-term Survival Data from ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association Announced Additional Validating Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mi

  • GlobeNewswire

    Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024

    MIAMI, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that it will report its 2023 financial results after the market close on February 27, 2024. The Company will host a conference call at 5:00 p.m. ET that day to discuss the Company’s results and provide a business update. TitleLongeveron Full Year 2023 Results Conference CallDate2/27/2